<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 獲取免費報告) 的股價在週五交易中下跌了 2.6%。該股票最低交易價為$12.56，最後交易價為$12.96。在午盤交易中，共交易了 778,019 股，較平均交易量 1,396,707 股下降了 44%。該股票此前收盤價為$13.31。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商最近對 PHAT 進行了評論。華爾街 Zen 在週六的研究報告中將 Phathom Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Phathom Pharmaceuticals 股票的 “賣出（d-）” 評級。一位投資分析師給予該股票 “強烈買入” 評級，四位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為$17.50。</p>
<p><strong>查看我們對 Phathom Pharmaceuticals 的最新股票分析</strong></p>
<h2>Phathom Pharmaceuticals 股票表現</h2>
<p>該公司的市值為 9.1938 億美元，市盈率為-2.74，貝塔值為 0.43。該公司的 50 日簡單移動平均線為$11.70，200 日簡單移動平均線為$8.31。</p>
<h2>機構投資者對 Phathom Pharmaceuticals 的看法</h2>
<p>對沖基金最近買入和賣出了該股票的股份。Jacobs Levy Equity Management Inc.在第一季度收購了 Phathom Pharmaceuticals 的新股份，價值約為$3,738,000。GAMMA Investing LLC 在第一季度將其在 Phathom Pharmaceuticals 的持倉提高了 797.2%。GAMMA Investing LLC 現在擁有該公司 4,558 股股票，價值$29,000，此前在上個季度購買了額外的 4,050 股。Russell Investments Group Ltd.在第一季度購買了 Phathom Pharmaceuticals 的新股份，價值約為$262,000。US Bancorp DE 在第一季度將其在 Phathom Pharmaceuticals 的持股增加了 248.1%。US Bancorp DE 現在擁有該公司 23,763 股股票，價值$149,000，此前在上個季度收購了額外的 16,937 股。最後，Wellington Management Group LLP 在第一季度將其在 Phathom Pharmaceuticals 的持股增加了 47.6%。Wellington Management Group LLP 現在擁有該公司 200,690 股股票，價值$1,258,000，此前在上個季度收購了額外的 64,695 股。機構投資者和對沖基金持有該公司 99.01% 的股份。</p>
<h2>關於 Phathom Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Phathom Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化治療胃腸疾病的藥物。該公司在美國、歐洲和加拿大擁有一種研究性鉀競爭性酸阻滯劑（P-CAB）的權利，該藥物可以阻止胃酸分泌。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Phathom Pharmaceuticals</li>
<li>現在值得購買的 3 只沃倫·巴菲特股票</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>英國市場假期是什麼？如何投資和交易</li>
<li>博通與 OpenAI 達成協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Phathom Pharmaceuticals 嗎？</h2>
<p>在你考慮 Phathom Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Phathom Pharmaceuticals 並不在名單上。</p>
<p>雖然 Phathom Pharmaceuticals 目前在分析師中有 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PHAT

<p>Phathom Pharmaceuticals（納斯達克代碼：PHAT）股價下跌 2.6%，至 12.96 美元，交易量較平均水平下降 44%。分析師的評級各不相同，其中一位給予強烈買入，四位給予買入，一位持有，一位賣出。該股票的評級為適度買入，市場共識目標價為 17.50 美元。機構投資者持有該公司 99.01% 的股份，該公司專注於胃腸疾病的治療。儘管近期股價下跌，一些分析師認為在 Phathom Pharmaceuticals 之外存在更好的投資機會</p>

<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s share price fell 2.6% during trading on Friday . The stock traded as low as $12.56 and last traded at $12.96. 778,019 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,396,707 shares. The stock had previously closed at $13.31.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 獲取免費報告) 的股價在週五交易中下跌了 2.6%。該股票最低交易價為$12.56，最後交易價為$12.96。在午盤交易中，共交易了 778,019 股，較平均交易量 1,396,707 股下降了 44%。該股票此前收盤價為$13.31。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages have recently commented on PHAT. Wall Street Zen raised Phathom Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.50.</p>
<div class="lb-trans"><p>幾家券商最近對 PHAT 進行了評論。華爾街 Zen 在週六的研究報告中將 Phathom Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Phathom Pharmaceuticals 股票的 “賣出（d-）” 評級。一位投資分析師給予該股票 “強烈買入” 評級，四位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為$17.50。</p>
</div><p><strong>View Our Latest Stock Analysis on Phathom Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Phathom Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Phathom Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 股票表現</h2>
</div><p>The company has a market cap of $919.38 million, a price-to-earnings ratio of -2.74 and a beta of 0.43. The business has a 50-day simple moving average of $11.70 and a 200-day simple moving average of $8.31.</p>
<div class="lb-trans"><p>該公司的市值為 9.1938 億美元，市盈率為-2.74，貝塔值為 0.43。該公司的 50 日簡單移動平均線為$11.70，200 日簡單移動平均線為$8.31。</p>
</div><h2>Institutional Investors Weigh In On Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Phathom Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Phathom Pharmaceuticals in the 1st quarter valued at about $3,738,000. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% in the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock valued at $29,000 after purchasing an additional 4,050 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at about $262,000. US Bancorp DE increased its holdings in shares of Phathom Pharmaceuticals by 248.1% in the 1st quarter. US Bancorp DE now owns 23,763 shares of the company's stock valued at $149,000 after acquiring an additional 16,937 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Phathom Pharmaceuticals by 47.6% in the 1st quarter. Wellington Management Group LLP now owns 200,690 shares of the company's stock valued at $1,258,000 after acquiring an additional 64,695 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該股票的股份。Jacobs Levy Equity Management Inc.在第一季度收購了 Phathom Pharmaceuticals 的新股份，價值約為$3,738,000。GAMMA Investing LLC 在第一季度將其在 Phathom Pharmaceuticals 的持倉提高了 797.2%。GAMMA Investing LLC 現在擁有該公司 4,558 股股票，價值$29,000，此前在上個季度購買了額外的 4,050 股。Russell Investments Group Ltd.在第一季度購買了 Phathom Pharmaceuticals 的新股份，價值約為$262,000。US Bancorp DE 在第一季度將其在 Phathom Pharmaceuticals 的持股增加了 248.1%。US Bancorp DE 現在擁有該公司 23,763 股股票，價值$149,000，此前在上個季度收購了額外的 16,937 股。最後，Wellington Management Group LLP 在第一季度將其在 Phathom Pharmaceuticals 的持股增加了 47.6%。Wellington Management Group LLP 現在擁有該公司 200,690 股股票，價值$1,258,000，此前在上個季度收購了額外的 64,695 股。機構投資者和對沖基金持有該公司 99.01% 的股份。</p>
</div><h2>About Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Phathom Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化治療胃腸疾病的藥物。該公司在美國、歐洲和加拿大擁有一種研究性鉀競爭性酸阻滯劑（P-CAB）的權利，該藥物可以阻止胃酸分泌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Phathom Pharmaceuticals</li>
<li>現在值得購買的 3 只沃倫·巴菲特股票</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>英國市場假期是什麼？如何投資和交易</li>
<li>博通與 OpenAI 達成協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Phathom Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Phathom Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Phathom Pharmaceuticals 並不在名單上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Phathom Pharmaceuticals 目前在分析師中有 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Phathom Pharmaceuticals（NASDAQ:PHAT）股價下跌 2.6% - 以下是原因